Drug Profile
AVX 502
Alternative Names: Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502); AVX502; Influenza virus vaccine - AlphaVax; Seasonal influenza vaccine for elderly - AlphaVaxLatest Information Update: 10 Mar 2021
Price :
$50
*
At a glance
- Originator AlphaVax
- Class Antivirals; Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 10 Mar 2021 Phase II development is ongoing in Influenza virus infections in USA (SC, IM) (AlphaVax pipeline, March 2021)
- 07 May 2018 Listed on Alphavax's pipeline, but no recent development has been reported
- 07 May 2018 Phase-II clinical trials in Influenza virus infections (In the elderly, Prevention, In adults) in USA (IM) (AlphaVax pipeline, May 2018)